Clinical trial
Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients With Higher Disease Activity (Anti-dsDNA Positive and Low Complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
NCT01858792 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients With Higher Disease Activity (Anti-dsDNA Positive and Low Complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- June 30, 2011
- Enrollment
- 1 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.